BCL2L1 and osteosarcoma: In this study we showed that inhibition of MCL-1 (with S63845) combined with inhibition of BCL-2 (with ABT-199) or BCL-xL (with A-1331852) consistently reduced the viability of osteosarcoma cells in vitro when drugs were applied at low micromolar concentrations (Fig. 1).